Every Form 4 that Crescent Capital BDC, Inc. (CCAP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CCAP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCAP filings page.
Crescent Capital BDC, Inc. (CCAP) reported that major stockholder Fidelity & Guaranty Life Insurance Company, a ten percent owner, filed a Form 4 for open-market sales of CCAP common stock executed under a Rule 10b5-1 trading plan. On September 8, 2026, an affiliated entity sold 126,436 shares at a volume weighted average price of $10.3322 in multiple trades within a $10.285–$10.45 range. On September 9, 2026, it sold a further 139,054 shares at a volume weighted average price of $10.2288 across trades in a $10.18–$10.28 range. The shares are held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) reported that Fidelity & Guaranty Life Insurance Company, a ten percent owner, filed to disclose open-market sales of a total of 15,482 shares of common stock on September 3–4, 2026, executed under a Rule 10b5-1 trading plan. The shares are held through Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary, and were sold in multiple transactions at volume-weighted average prices.
Crescent Capital BDC, Inc. (CCAP) reported that Fidelity & Guaranty Life Insurance Company, a ten percent owner, sold a total of 56,285 shares of Common Stock in open-market or private transactions on September 1 and September 2, 2026, under a Rule 10b5-1 trading plan.
The reported sales consisted of 11,285 shares at $10.50 per share on September 1 and 45,000 shares at a volume-weighted average price of about $10.44 per share on September 2, with execution prices ranging from $10.38 to $10.59. Some of the reported holdings are owned by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) reported that ten percent owner Fidelity & Guaranty Life Insurance Company sold shares of its common stock in late August 2026. The reporting person sold 15,000 shares on August 28, 2026 at a volume-weighted average price of $10.6020 and 40,000 shares on August 31, 2026 at a volume-weighted average price of $10.6205, both as open-market transactions under a Rule 10b5-1 trading plan. Footnotes state that the shares were sold in multiple trades within disclosed price ranges and that some shares are held through a wholly owned New York insurance subsidiary.
Crescent Capital BDC, Inc. (CCAP) reported that Fidelity & Guaranty Life Insurance Company, a ten percent owner, sold a total of 59,286 shares of common stock in two open-market transactions on August 26 and 27, 2026, at volume-weighted average prices around $10.60 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan, and some shares are held through Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) had a Form 4 filed by Fidelity & Guaranty Life Insurance Co, a ten percent owner, reporting net open-market sales of 73,457 shares of common stock. The sales on 2026-08-24 and 2026-08-25, executed under a Rule 10b5-1 trading plan, were made at volume-weighted average prices around $10.72–$10.80 per share. A portion of the reported shares is held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) officer and director Henry Chung reported a purchase of 2,500 shares of Common Stock on August 19, 2026 at $10.89 per share in an open-market or private transaction. Following this transaction, he directly held 23,917 shares, which includes 695 shares acquired through dividend reinvestment in 2026 that had not been previously reported under Rule 16a-11.
Crescent Capital BDC, Inc. (CCAP) reported that Chief Financial Officer Lombard Gerhard purchased 2,000 shares of common stock on 2026-08-19 in an open-market transaction at a weighted average price of $10.91 per share. Following this trade and previously unreported dividend reinvestments, his direct holdings total 40,509 shares.
Crescent Capital BDC, Inc. president and director Henry Chung reported an open‑market purchase of 4,500 shares of common stock at $11.45 per share on May 21, 2026. Following this transaction, he directly holds 20,722 shares, including 945 shares acquired through dividend reinvestment in 2026.
Crescent Capital BDC, Inc. Chief Executive Officer Jason Breaux bought additional company stock in an open-market transaction. On May 20, 2026, he purchased 5,000 shares of Common Stock at $11.19 per share. Following this purchase, his direct holdings increased to 52,636 shares of Crescent Capital BDC, Inc. Common Stock.
Crescent Capital BDC, Inc. Chief Financial Officer Gerhard Lombard bought 1,000 shares of common stock in an open-market purchase at $11.12 per share on 2026-05-18. This is a direct ownership transaction.
After this trade, Lombard directly owns 37,373 common shares. This figure includes 2,088 shares acquired through dividend reinvestment in 2026, which were not previously reported under Rule 16a-11.
Crescent Capital BDC, Inc. director Steven F. Strandberg reported an indirect open-market purchase of common stock through the Diana and Steven Strandberg Revocable Trust. On May 19, 2026, the trust bought 85,000 shares at a weighted average price of $11.2763 per share in multiple trades priced between $11.11 and $11.35. Following these transactions, the trust’s indirect holdings attributed to Strandberg increased to 201,135 shares of Crescent Capital BDC common stock.
Crescent Capital BDC, Inc. (CCAP) reported an insider share purchase by its Chief Financial Officer on a Form 4. On 11/17/2025, the CFO bought 2,000 shares of common stock in an open market transaction coded as a purchase.
The weighted average purchase price was $13.3415 per share, with individual trades executed between $13.34 and $13.3499. After this transaction, the CFO beneficially owned 34,284 shares of CCAP common stock.
This total includes 2,627 shares acquired during 2025 through dividend reinvestment that had not been previously reported. The filing notes that full trade price details are available to regulators, the company, or any security holder upon request.